Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10746MR)

This product GTTS-WQ10746MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10746MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12216MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ717MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ1700MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ12949MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ11277MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ1774MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ2445MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ991MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW